Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crinetics Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crinetics Pharmaceuticals's regulatory disclosures and financial reporting.
CRNX files a Form 144 disclosing proposed resale transactions of its Common Stock. The notice lists a reported sale of $370,411.47 for 9,911 shares on 03/16/2026. The filing also itemizes securities related to exercise of stock options (78,434 shares, 04/08/2026), an Employee Stock Purchase Plan entry (438 shares, 05/20/2025), and Restricted Stock Units (6,291 shares, 03/15/2024).
The Form 144 is a notice of proposed sale by an affiliate and describes the method of sale as cash transactions. It reports the broker/dealer and issuer entries tied to each lot; the filing does not state additional proceeds disposition or timing beyond the listed dates.
Crinetics Pharmaceuticals receives an amended Schedule 13G from The Vanguard Group reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under which certain Vanguard subsidiaries report holdings separately.
The filing is signed March 26, 2026 by Ashley Grim, Head of Global Fund Administration, and lists Vanguard's Malvern, Pennsylvania address and Crinetics' principal executive office in San Diego.
Crinetics Pharmaceuticals announced that Jeff Knight has decided to resign as Chief Development and Operating Officer, effective on or about April 10, 2026. The company states that he is leaving to pursue another opportunity and that his resignation is not due to any disagreement over operations, policies, or practices.
Crinetics plans to reassign all of Mr. Knight’s managerial responsibilities and direct reports to other members of its executive leadership team, signaling a redistribution of his duties rather than the creation of a new replacement role at this time.
Crinetics Pharmaceuticals Chief Operating Officer Jeff E. Knight sold 9,911 shares of common stock in open-market transactions. The sales on March 16, 2026 were executed at volume-weighted average prices of $37.11 and $37.77 per share.
According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of previously granted restricted stock units and were carried out by a broker under a Rule 10b5-1 trading plan. After the transactions, Knight directly holds 112,018 shares of Crinetics common stock.
Crinetics Pharmaceuticals Chief Scientific Officer Stephen F. Betz reported selling a total of 10,612 shares of common stock on March 16, 2026 in open-market transactions. One block of 6,371 shares was sold at a volume-weighted average price of $37.11 per share, and another 4,241 shares at $37.77 per share.
According to the footnotes, these sales were made to cover his tax withholding obligations upon the vesting of previously granted restricted stock units and were executed by a broker under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Betz directly holds 137,101 shares of Crinetics common stock.
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported tax-related share sales. On March 16, 2026, he sold a total of 21,981 shares of common stock in open-market transactions, including 13,196 shares at a volume-weighted average price of $37.11 and 8,785 shares at $37.77.
According to the disclosure, these shares were sold by a broker to cover the CEO's tax withholding obligations upon the vesting of restricted stock units granted on February 28, 2022, March 1, 2023, and March 4, 2024, under a Rule 10b5-1 trading plan. After the sales, he directly holds 404,778 shares of common stock and has additional indirect holdings through several family trusts and his spouse.
CRNX: Notice of proposed and recent insider sales of Common Stock
The filing lists proposed transactions and recent dispositions by an insider. It shows a proposed exercise of stock options to sell 15,000 shares03/18/2026 and proposed settlement of 9,756 Restricted Stock Units03/15/2026. The filing also discloses three 10b5-1 sales of 5,000 shares each01/02/2026, 02/02/2026, and 03/02/2026 with proceeds of $232,590.50, $247,485.50, and $202,234.00, respectively.